| Trial ID: | L0097 |
| Source ID: | NCT01049711
|
| Associated Drug: |
Erythropoietin
|
| Title: |
Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients
|
| Acronym: |
CUAEPO
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Failure
|
| Interventions: |
DRUG: erythropoietin
|
| Outcome Measures: |
Primary: The utility scores of hemodialysis (HD) patients who use EPO to maintain the Hb target level., 1 year|Cost of HD patients who use EPO to maintain the Hb target level., 1 year | Secondary: The incremental cost-effectiveness ratio (calculated as the ratio between the incremental differences in costs and QALYs associated with 2 alternative treatments) of EPO at the different Hb target levels in HD patients in routine clinical practice., lifetime horizon (Economic evaluation term)
|
| Sponsor/Collaborators: |
Sponsor: Mahidol University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
152
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2009-11
|
| Completion Date: |
2010-09
|
| Results First Posted: |
|
| Last Update Posted: |
2015-09-29
|
| Locations: |
Siriraj Hospital, Bangkok, Thailand
|
| URL: |
https://clinicaltrials.gov/show/NCT01049711
|
